Investing.com - H.C. Wainwright在 Corbus Pharmaceuticals （纳斯达克：CRBP）在ESMO 2025上展示CRB-701的1/2期数据后，重申了其"买入"评级和40.00美元的目标价。目前该公司市值为2.3677亿美元。该股表现出显著的增长势头，过去六个月内上涨了220.4%，分析师目标价范围在28美元至55美元之间。

ORR of 47.6% in HNSCC, 37.5% in cervical cancer and 55.6% in mUCCRB-701 continues to demonstrate a favorable safety and ...

Investing.com - 派博桑德勒 (Piper Sandler)周一将 Corbus制药 (Corbus Pharmaceuticals) (NASDAQ:CRBP)的目标价从35.00美元上调至51.00美元，同时维持对该股的"增持"评级。该公司目前市值为2.3677亿美元，过去一周股价飙升18.38%，分析师维持强烈买入共识。根据 InvestingPro ...

The excitement of cricket fans in Bangladesh reached new heights as the trophy for the highly anticipated Bangladesh-West Indies T20 series was unveiled at the Central Railway Building (CRB) in ...

Corbus Pharmaceuticals Holdings (($CRBP)) announced an update on their ongoing clinical study. Corbus Pharmaceuticals Holdings is conducting a ...

Data to be presented for 167 enrolled participants of which 122 were evaluable for efficacy Company to host HNSCC KOL event ...

Investing.com -- Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) stock jumped 9.5% in Monday premarket trading after the company reported promising efficacy data for its cancer treatment CRB-701 in ...

The Credit Reference Bureau (CRB) is an organization that collects and maintains data on an individual’s or company’s credit ...